Navigation Links
Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
Date:4/24/2012

(FSH) were 40 or more milli international units/milliliter, a marker of menopause. The women were in good health. Investigators did not enroll anyone with a history of breast, ovarian or uterine cancer or endometrial hyperplasia, with a body mass index of 33 kg/m2 or more or who had used hormone replacement therapy within 90 days of the study or soy, phytoestrogens or certain other supplements within 30 days of the study, as well as fitting certain other exclusion criteria.

Investigators randomized the 102 women into four groups to consume twice daily either the isoflavone (26 women) or one of the three doses of the S-equol supplement (24 in the 10 mg, 27 in the 20 mg and 25 in the 40 mg groups). The lowest dose of S-equol used, 10 mg, was based on preliminary studies that investigated the relationship between S-equol and menopausal symptoms including hot flashes in Japanese women, while the higher doses were used to reflect the larger body mass in Western women and to establish a dose response. The S-equol supplement tablets each contained 5.0 mg S-equol, 1.0 mg daidzein, 1.1 mg genistein, and 2.5 mg glycitein. The soy isoflavone tablets contained 24 mg daidzein, 22 mg genistein, and 2.0 mg glycitein as aglycone equivalent. The placebo tablets contained lactose.

The women had diets controlled for soy foods, isoflavones and lignans, compounds found in certain plants that are known as phytoestrogens because of their estrogen-like properties. The study included a seven-day period before the treatment weeks to allow for elimination of any women who responded to a placebo. Women also were tested to determine their ability to produce S-equol after eating soy. The study included 72 percent equol nonproducers and 28 percent equol producers, which represents the previously reported US equol producer ratio. The investigators randomized the equol producers equally into each of the study's treatment groups.

No previous studies have report
'/>"/>

Contact: Stephen McCauley
smccauley@porternovelli.com
202-973-3615
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Soy-based natural S-equol supplements improve crows feet skin wrinkles in menopausal women
2. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
3. Model for breast cancer rehab featured in supplement to ACS journal, Cancer
4. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
5. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
6. Vitamin E Supplements Dont Affect Heart Failure Risk: Study
7. Vitamin A Supplements Might Cut Melanoma Risk: Study
8. Selenium Supplements May Help -- or Harm
9. Soy isoflavone supplements did not provide breast cancer protections
10. Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer
11. Researchers identify phthalates in numeruous medicines and supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Dr. Diane Walder, one of South Florida’s top cosmetic ... called Ultrashape that is designed to help her patients reduce ... weeks. Ultrashape has been praised by patients as being permanent, ... to other types of external fat reduction. , “If you ... , According to Dr. Walder, Ultrashape works by targeting ...
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5
... - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Mellow ... that its clinical trial is currently being processed. The company ... days). The company expects the manufacturing license will be released ... to as "swine flu" early on) is a new influenza ...
... Hospitals, Physicians Work Together to Cut Costs, Improve ... 18 Twelve New Jersey hospitals and their participating physicians have ... incentive method that aims to reduce healthcare costs while improving quality ... could serve as a basis to overhaul government payment for Medicare ...
... , , LOS ANGELES, Aug. ... El Cancer (PADRES), a non-profit organization committed to improving the quality ... celebrate its ninth annual fund-raising gala, " EL SUENO DE ESPERANZA ... pay tribute to PADRES, extraordinary children and families, while at the ...
... speed, report shows , TUESDAY, Aug. 18 (HealthDay News) ... viral infection norovirus from a novel source: a tobacco ... tobacco plant using a bioengineered plant virus. , This ... ways to bring vaccines to the public quickly, especially ...
... PHILADELPHIA, Aug. 18 EwingCole, a nationally ... more than 320 professionals, today announced that it will ... Philadelphia, a 40-person firm with a robust portfolio of ... to take effect by September 1, 2009, will create ...
... , , , AUSTIN, ... a full-service pet travel company providing worldwide door-to-door pet trans ... pet health resource, P e tMD , to ... , The strategic affiliation will allow guests of PetMD to ...
Cached Medicine News:Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 2Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 2Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 3Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 4Health News:'Cruise Ship Virus' Vaccine Stems From Tobacco 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 3
(Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen (NASDAQ: ... ) today announced that AMAGINE-2 TM , a pivotal, multi-arm ... than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary ... placebo at week 12. Brodalumab 210 mg given every two ... to be superior to Stelara on the primary endpoint of ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... (Nasdaq: OMCL ), a leading provider of system ... quarter and year ended December 31, 2010. ... was $57.3 million, up $1.0 million or 1.7% from the ... from the fourth quarter of 2009.  Revenue for the year ...
... Thoratec Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts, said today that revenues ... over those in fiscal 2009. Results from ... quarter of fiscal 2010 and 2009 exclude contributions from ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full Year 2010 Results 2Omnicell Announces Fourth Quarter and Full Year 2010 Results 3Omnicell Announces Fourth Quarter and Full Year 2010 Results 4Omnicell Announces Fourth Quarter and Full Year 2010 Results 5Omnicell Announces Fourth Quarter and Full Year 2010 Results 6Omnicell Announces Fourth Quarter and Full Year 2010 Results 7Omnicell Announces Fourth Quarter and Full Year 2010 Results 8Omnicell Announces Fourth Quarter and Full Year 2010 Results 9Omnicell Announces Fourth Quarter and Full Year 2010 Results 10Omnicell Announces Fourth Quarter and Full Year 2010 Results 11Omnicell Announces Fourth Quarter and Full Year 2010 Results 12Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 2Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 3Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 4Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 5Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 6Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 7Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 8Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 9Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 10Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 11Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 12Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 13Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 14Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations 15
... The ABI PRISM 310 Genetic Analyzer ... for a wide range of sequencing and ... for academic and forensic labs who incorporate ... Genetic Analyzer -- the ideal alternative to ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: